newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

EIKN
  • Eikon Therapeutics presented updated data on EIK1001 & EIK1003 at the 2026 ASCO Annual Meeting in Chicago.
  • The TeLuRide-005 Phase 2 trial of EIK1001 in stage 4 NSCLC completed enrollment of non-squamous & squamous cohorts in Q1 2026.
  • Among 72 evaluable patients in TeLuRide-005, EIK1001 combined with pembrolizumab & chemotherapy showed a 63.1% objective response rate (ORR) & 90.8% disease control rate (DCR).
  • The non-squamous cohort demonstrated a 55.6% ORR with a median duration of response exceeding 11 months.
  • The squamous cohort showed a 72.4% ORR & 100% DCR, though the dataset was still maturing due to slower enrollment.
  • EIK1001 demonstrated a tolerability profile suitable for outpatient administration, with most adverse events being Grade 1-2 & all cytokine release syndrome events occurring before Cycle 4.
  • The Phase 1/2 EIK1003-001 trial reported updated monotherapy data showing a 14.3% overall ORR in 49 evaluable patients with advanced solid tumors.
  • Initial combination data for EIK1003 with weekly paclitaxel revealed a 24.5% ORR in 53 evaluable patients with platinum-resistant ovarian or HER2-negative breast cancer.
  • EIK1003 is a highly selective PARP1 inhibitor designed to leave PARP2 signaling intact, potentially reducing hematological toxicity compared to non-selective inhibitors.
  • Six abstracts detailing progress on EIK1001, EIK1003, & the novel WRN inhibitor EIK1005 will be presented at ASCO 2026.